The human integrin avß6, which is usually undetectable in normal adults cells, but highly upregulated in different types of cancer, is an emerging target for therapy as well as imaging across several common tumor types. However, only few ligands are known so far that are highly active for avß6 integrin and at the same time possess no binding afﬁnity toward other RGD-recognizing integrins. Furthermore, their metabolic instability, their high molecular weight and the complexity of their structures limit their medical application. This problem could now be solved by the present invention. The peptides according to the invention show a remarkable affinity for avß6 and high selectivity against other integrins.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences